Generation Essentials Group, Phio Pharmaceuticals, and Caribou Biosciences are the 3 Penny Stocks to watch on November 4, 2025, based on TipRanks’ Penny Stock Screener tool. Penny stocks are defined as stocks that trade at or below $5 per share and have a market capitalization below $300 million.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The Penny Stock Screener helps investors scan stocks based on numerous parameters, including Sector, Price Target Upside, Smart Score, Analyst Consensus, Dollar Volume, and Price Change.
We leveraged the tool to pick the top three penny stocks with the highest Dollar Volume as of the close on November 3, 2025. Simply put, Dollar Volume is the number of shares traded on a particular day multiplied by the day’s share price.
Generation Essentials Group (TGE) – Generation Essentials Group is a France-based media and entertainment company. On November 3, TGE had a Dollar Volume of $308 million, while its stock price rocketed by 123%.
The company announced a share repurchase program of up to $5 million until January 31, 2026, stating that its shares are undervalued. It is worth noting that Generation Essentials is a subsidiary of AMTD Digital (HKD). Yesterday, the Group announced that it is in active talks with several parties to potentially acquire hotels worldwide, including one in New York City that is under exclusive negotiation. It aims to grow its hotel portfolio to over 1,000 rooms within 12 to 15 months.
Phio Pharmaceuticals (PHIO) – Phio Pharmaceuticals is a clinical-stage biotech company focused on developing immuno-oncology therapeutics. On Monday, PHIO had a Dollar Volume of $301.44 million, while its shares declined by 9.3%.
The day’s decline follows an initial surge in PHIO shares, which were up nearly 75% in early trading. The company announced positive treatment outcomes for three patients with cutaneous squamous cell carcinoma in a Phase 1b trial using its proprietary INTASYL gene-silencing technology. One patient achieved 100% tumor elimination, another over 90%, and the third over 50%, with assessments made about five weeks after treatment began.
Caribou Biosciences (CRBU) – Caribou Biosciences is a clinical-stage biotech company focused on developing CRISPR gene-editing technology to develop innovative therapies for oncology and autoimmune disorders. Yesterday, CRBU had a Dollar Volume of $166.10 million, while its stock price hit a fresh 52-week high of $3.54 in early trading.
CRBU stock jumped on multiple catalysts. Citi analyst Yigal Nochomovitz raised his price target from $5 to $8 and maintained a “Buy” rating, citing “meaningfully increased conviction” in the allogenic CAR-T value proposition. Caribou announced two strong data results in patients with difficult-to-treat B cell non-Hodgkin lymphoma and multiple myeloma. These results show that Caribou’s allogeneic therapies are effective and comparable to existing autologous CAR-T therapies and bispecific treatments, fulfilling the company’s goals for strong efficacy.
To find more penny stocks like these, you can take a look at TipRanks’ Penny Stock Screener tool. It shows a list of all penny stocks, their price movement, and other vital data.